Indian Journal of Public Health Research & Development

K. Vivek ¹, G. Jagan ²

Affiliations
1 Sree Balaji Medical College & Hospital, Bharath Institute of Higher Education and Research, Chennai, IN
2 Department of General medicine,Sree Balaji Medical College & Hospital, Bharath Institute of Higher Education and Research, Chennai, IN

Abstract

The purpose of this study was to assess the safety and preliminary clinical results of platelet-rich plasma (PRP) injections for treating chronic plantar fasciitis. The present sample size of 40 patients were analysed prospectively by injecting platelet rich plasma in plantar fasciitis. The study was conducted in sreebalaji medical college and hospital from March 2017 to March 2018 with a follow up period of 3 months duration. The visual analogue scales (VAS) for pain were used to evaluate the clinical results. The mean difference between in VAS scoring system at the time of presentation was 8.4%, and there was gradual and significant improvement in VAS scoring system in plantar fasciitis. Which showed as 4.925% at 1^st month, 3.375% at 2^nd month, and 1.925% at 3^rd month respectively. In this single-centre, uncontrolled, prospective, preliminary study, results indicate that treating chronic plantar fasciitis with PRP injections is safe and has the potential to reduce pain.

Keywords

Platelet Rich Plasma, Plantar Fasciitis.

Full Text

     

T. Manivel ¹, G. Jagan ¹

Affiliations
1 Department of General medicine, Sree Balaji Medical College and Hospital, Bharath Institute of Higher Education and Research, Chennai-73, IN

Abstract

Aim: To evaluate the efficacy of metformin monotherapy in newly diagnosed type 2 mellitus patients by assessing the hba1c reduction percentage and thereby preventing the incidence of macrovascular complications.

Materials and Method: A total of 50 type 2 diabetes mellitus patients were included in the study.and after obtaining the informed consent the patients were advised to take Tablet metformin 500mg twice daily and hba1c were done at baseline, 3 and 6 months of the study period and the patients were assessed periodically and if any adverse events were reported it was recorded and manged promptly.

Results: HBA1C baseline value expressed as Mean±SD was 7.966±0.85 %. After 3 months of metformin therapy, HBA1C mean obtained was 7.53±0.83 %. After 6 months of metformin therapy, HBA1C improved to 6.8±0.93. Treatment with Metformin showed effective reduction in HBA1C values comparatively between HBA1C baseline values and HBA1C values at sixth month were statistically significant(P<0.05).

Conclusion: From the above results the current study shows significant reduction in hba1c values after six months of metformin therapy and this proves that metformin is a sole antidiabetic agent started as monotherapy in newly diagnosed diabetic patients the incidence of macrovascular complications can be prevented at the intial stage of the disease.

Keywords

Metformin, Macrovascular, Type 2 Diabetes Mellitus.

Full Text